Atrophic Vaginitis
6
Pipeline Programs
3
Companies
3
Clinical Trials
3
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
2
3
Early DiscoveryClinical DevelopmentMarket
On Market (3)
Approved therapies currently available
U
ESCLIMApproved
estradiol
Unknown Companytransdermal1998
U
GYNODIOLApproved
estradiol
Unknown Companyoral1997
U
IMVEXXYApproved
estradiol
Unknown CompanyEstrogen [EPC]vaginal2018
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
TevaGeneric Estradiol Vaginal Cream USP, 0.01%
AlvogenEstradiol
PfizerPremarin® Vaginal Cream
Clinical Trials (3)
Total enrollment: 1,222 patients across 3 trials
Study to Evaluate Equivalence of Estradiol Vaginal Cream 0.01% to Estrace® Cream 0.01% in Atrophic Vaginitis
Start: May 2016Est. completion: Feb 2017663 patients
Phase 3Completed
A Study Comparing Estradiol Vaginal Cream to Estrace® Cream in Females With Atrophic Vaginitis
Start: Mar 2016Est. completion: Dec 2016535 patients
Phase 3Completed
Study Comparing Premarin® Vaginal Cream Versus Premarin® Oral Tablets in Atrophic Vaginitis
Start: Oct 200524 patients
Phase 1Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 late-stage (Phase 3) programs — potential near-term approvals
3 companies competing in this space